Digital Therapeutic for Schizophrenia
CT-155, a smartphone app, has shown promising results in reducing negative symptoms of schizophrenia.
Developed by Boehringer Ingelheim and Click Therapeutics, CT-155 integrates psychosocial interventions using an adaptive goal-setting technique.
A phase 3 trial demonstrated its effectiveness, with data presented at the 38th Annual European College of Neuropsychopharmacology Congress.
A prescription digital therapy has demonstrated that it can reduce the negative symptoms of schizophrenia.
An estimated 24 million people worldwide have schizophrenia, according to the World Health Organization, characterized by persistent delusions and hallucinations.
CT-155 is the first experimental prescription digital therapy to show good tolerability and no significant adverse events when used with antipsychotic treatment.
Author's summary: Digital therapy CT-155 reduces schizophrenia symptoms.